Key Points
- Carl Dambkowski sold 5,500 Apogee shares on March 4 at an average price of $71.06 for $390,830, trimming his position by 2.55% to 209,773 shares valued at about $14.9M; this follows sales on Feb. 4 and Jan. 7 totaling an additional 24,200 shares.
- Apogee shares opened at $73.05 (up ~3%), trade in a 52-week range of $26.20–$84.56 with a market cap of $5.08B and a negative P/E, while analysts hold a consensus "Moderate Buy" with a $104.92 average price target and institutions own roughly 79% after large buys by T. Rowe Price, Janus and others.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $71.06, for a total value of $390,830.00. Following the completion of the transaction, the insider owned 209,773 shares of the company's stock, valued at $14,906,469.38. This trade represents a 2.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Carl Dambkowski also recently made the following trade(s):
- On Wednesday, February 4th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $65.79, for a total value of $361,845.00.
- On Wednesday, January 7th, Carl Dambkowski sold 18,700 shares of Apogee Therapeutics stock. The stock was sold at an average price of $77.84, for a total value of $1,455,608.00.
Apogee Therapeutics Stock Up 3.0%
Shares of NASDAQ APGE opened at $73.05 on Friday. Apogee Therapeutics Inc. has a 52 week low of $26.20 and a 52 week high of $84.56. The business's 50 day moving average price is $72.38 and its 200 day moving average price is $60.66. The firm has a market cap of $5.08 billion, a P/E ratio of -17.31 and a beta of 1.39.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.02. As a group, research analysts expect that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the company. Wall Street Zen downgraded Apogee Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, December 6th. Craig Hallum restated a "buy" rating and issued a $116.00 target price on shares of Apogee Therapeutics in a research note on Wednesday, January 7th. Citigroup reaffirmed a "buy" rating on shares of Apogee Therapeutics in a report on Sunday, January 25th. Deutsche Bank Aktiengesellschaft began coverage on Apogee Therapeutics in a research report on Tuesday, December 9th. They set a "buy" rating and a $103.00 price target for the company. Finally, Royal Bank Of Canada dropped their price objective on shares of Apogee Therapeutics from $83.00 to $82.00 and set a "sector perform" rating on the stock in a research note on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Apogee Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $104.92.
Check Out Our Latest Analysis on Apogee Therapeutics
Hedge Funds Weigh In On Apogee Therapeutics
Hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. grew its holdings in Apogee Therapeutics by 189,522.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company's stock valued at $206,246,000 after purchasing an additional 2,731,015 shares during the period. Janus Henderson Group PLC lifted its position in shares of Apogee Therapeutics by 324.4% during the 4th quarter. Janus Henderson Group PLC now owns 2,062,604 shares of the company's stock valued at $155,697,000 after buying an additional 1,576,626 shares in the last quarter. Perceptive Advisors LLC grew its stake in Apogee Therapeutics by 72.4% in the 4th quarter. Perceptive Advisors LLC now owns 2,330,651 shares of the company's stock valued at $175,918,000 after acquiring an additional 978,662 shares during the period. Wellington Management Group LLP increased its holdings in Apogee Therapeutics by 24.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company's stock worth $187,673,000 after acquiring an additional 917,991 shares in the last quarter. Finally, UBS Group AG raised its position in Apogee Therapeutics by 646.1% during the third quarter. UBS Group AG now owns 799,465 shares of the company's stock worth $31,763,000 after acquiring an additional 692,308 shares during the period. Hedge funds and other institutional investors own 79.04% of the company's stock.
Apogee Therapeutics Company Profile
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
